FAM224A/hsa-mir-139/RAD54B is a Competing Endogenous RNA Network that may Serve as a New Prognostic Factor and Treatment Target for Liver Cancer

Abstract

The potential of long noncoding RNAs (lncRNAs) as symptomatic and prognostic biomarkers in oncotherapy for hepatic carcinoma has been revealed. However, the specific mechanisms of lncRNAregulated tumor progression and metastasis are not completely known. The RNA and miRNA sequencing data of liver cancer in The Cancer Genome Atlas database were analyzed. A competing endogenous RNA (ceRNA) was constructed, and its effects on the progression and metastasis of tumors and the survival rates of patients with tumor were evaluated. Differentially expressed mRNAs, miRNAs, and lncRNAs were identified. A liver cancer-associated ceRNA network, namely, FAM224A/hsa-mir-139/RAD54B, was then established. FAM224A/hsa-mir-139/RAD54B assumed a significant part in liver malignancy movement and metastasis. A series of cell experiments was conducted to prove the importance of ceRNAs, and the binding between RNAs was validated through a dual-luciferase reporter assay. The FAM224A/hsa-mir-139/RAD54B network in liver cancer was identified. FAM224A may be an important prognostic factor and treatment target for liver cancer.